Lorazepam is a benzodiazepine with CNS depressant, anxiolytic and sedative properties.
Peak serum concentrations of free lorazepam after oral administration are reached in 1 to 6
hours. Peak concentrations are reached in 60 to 90 minutes after i.m. administration and in 60
minutes after sublingual administration. Lorazepam is 85% bound to plasma proteins.
Lorazepam is rapidly conjugated to an inactive glucuronide. Very small amounts of other
metabolites have also been isolated in man. The serum half-life of lorazepam is
approximately 12 to 15 hours while the half-life of the conjugate is 16 to 20 hours. Ninety-
Myasthenia gravis, acute narrow angle glaucoma, known hypersensitivity to benzodiazepines.
Lorazepam injectable is also contraindicated in patients with known hypersensitivity to
polyethylene glycol, propylene glycol or benzyl alcohol.
Lorazepam should not be injected intraarterially and care should be taken to prevent its
extravasation into tissue adjacent to an artery because of the danger of producing
arteriospasm resulting in gangrene which may require amputation.
Lorazepam is not recommended for use in depressive neurosis or in psychotic reactions.
Because of the lack of sufficient clinical experience, lorazepam is not recommended for use
in patients less than 18 years of age. Since lorazepam has a CNS depressant effect, patients
should be advised against the simultaneous use of other CNS depressant drugs. Patients
should also be cautioned not to take alcohol during the administration of lorazepam because
of the potentiation of effects that may occur.
Excessive sedation has been observed with lorazepam at standard therapeutic doses.
Therefore, patients should be warned against engaging in hazardous activities requiring
mental alertness and motor coordination, such as operating dangerous machinery or driving
Prior to i.v. use, lorazepam injection should be diluted with an equal amount of compatible
diluent (see Dosage). I.V. injection should be made slowly and with repeated aspiration. Care
should be taken to determine that any injection will not be intraarterial and that perivascular
extravasation will not take place. Partial airway obstruction may occur in heavily sedated
patients. I.V. lorazepam, when given alone in greater than the recommended dose, or at the
recommended dose and accompanied by other drugs used during the administration of
anesthesia, may produce heavy sedation; therefore, equipment necessary to maintain a patent
airway and to support respiration/ventilation should be available.
As with any premedicant, extreme care must be used in administering lorazepam injection to
elderly or very ill patients and to those with limited pulmonary reserve, because of the
possibility that apnea and/or cardiac arrest may occur. Because of the lack of sufficient
clinical experience lorazepam injection is not recommended for use in patients less than 18
years of age.
This action might not be possible to undo. Are you sure you want to continue?